The 2026 American Diabetes Association Scientific Sessions runs June 5-8 in New Orleans and is the year's most concentrated diabetes-and-metabolic-disease data event. Several Phase 3 readouts and pivotal preclinical presentations are scheduled across the major peptide therapeutic programs.
Confirmed peptide-relevant slate: Eli Lilly retatrutide TRIUMPH program (multiple of the seven 2026 readouts expected to land at ADA); Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal data with rodent weight-loss superiority over retatrutide (May 29 Poster 2839-LB); AstraZeneca eleglipron (formerly elecoglipron/AZD5004/ECC5004) full Phase 2b VISTA and SOLSTICE data after the April 29 topline; Innovent mazdutide Phase 3 GLORY-2 (18.55% mean weight reduction) and head-to-head DREAMS-3 vs semaglutide; and Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data after the April 28 topline of 16.6% mean weight loss.
The meeting also covers Pfizer berobenatide (MET-097i) Phase 3 VESPER program updates and earlier-stage peptide-receptor work across endocrine indications. Stories here cover trial readouts, plenary sessions, and the broader peptide-and-incretin slate at ADA. See #retatrutide, #mazdutide, and #survodutide.
Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.
Hanmi Pharmaceutical presented HM500197 (LA-MSTN) at ADA 2026 (June 5-8, New Orleans) as the world's first peptide-based myostatin inhibitor, positioned as a muscle-preserving adjunct to GLP-1 weight-loss therapy. The molecule was designed on Hanmi's HARP (Hanmi AI-driven Research Platform) integrating AI and structural modeling. Hanmi paired the LA-MSTN unveiling with a second next-generation candidate, HM17321, in a broader eight-abstract slate spanning the company's obesity pipeline. The myostatin angle addresses a major shortcoming of the current GLP-1 class — 25-40% of weight loss coming from lean tissue rather than fat — which Stanford's Maharjan team flagged at ENDO 2026 with the 560-step daily activity drop and which underlies the broader bone-health and frailty concerns now being studied across the GLP-1 class.
Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.
Pfizer presented Phase 2b VESPER-1 data for berobenatide (PF-07976094 / PF'3944), the ultra-long-acting injectable GLP-1 peptide engineered for monthly dosing through a 0.5 mL low-volume injection. At ADA 2026, the 2.4 mg weekly dose drove up to 15.9% mean weight loss at 32 weeks with no plateau across the VESPER program, plus improved glycemic control and favorable tolerability. Pfizer plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of berobenatide in chronic weight management, knee osteoarthritis, and obstructive sleep apnea. The asset entered Pfizer's pipeline through the $4.9 billion Metsera acquisition.
The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
BioPharma Dive's June 8 ADA wrap framed the meeting's competitive sort: Lilly reinforced its lead with retatrutide (28.3%) and Foundayo's head-to-head win over oral semaglutide; Pfizer's berobenatide emerged as 'foundational' with the monthly-dosing differentiation; Roche's enicepatide drew 'me-too' framing from RBC's Trung Huynh ('does little to differentiate enicepatide from its peers'). Novo Nordisk lost ground after CagriSema missed non-inferiority versus its target competitor on some endpoints. Lilly closed about 4.5% higher Monday on the data; Novo fell 3.46%.
Novo Nordisk closed 3.46% lower Monday June 8 as investor attention focused on Lilly's clear ADA win and on CagriSema's failure to demonstrate non-inferiority against a competitor on some obesity endpoints. CVS Caremark's earlier formulary tilt toward Lilly's Zepbound (announced in late May, effective October 1) and the broader oral GLP-1 picture compound the pressure. Novo's Wegovy pill remains the only US-approved oral, but the next-wave pipeline narrative now skews to Lilly.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
While the ADA stage belonged to Lilly and Novo, Korea Biomedical Review covered the Korean biotechs that sidestepped the headline duel and pitched monthly GLP-1s and next-wave obesity technologies. Hanmi Pharmaceutical, D&D Pharmatech, and Onegene Biotechnology made the case for differentiated dosing intervals, novel-mechanism peptides, and Asia-Pacific market positioning. The pattern echoes Chinese entrants like Innovent (mazdutide), Hengrui (ribupatide, HRS-7535), and Sciwind, and reinforces a meeting-wide pattern: the obesity field is broadening into a global, multi-mechanism pipeline.
Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.
AstraZeneca presented VISTA Phase 2b data at ADA 2026 with simultaneous Lancet publication. In adults with obesity or overweight plus comorbidity, oral elecoglipron 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, continuing to 11.8% by 36 weeks, alongside blood-pressure and inflammation reductions. The companion SOLSTICE T2D trial showed 1.9-point HbA1c reductions with 90% reaching HbA1c under 7% and 7.7% weight loss. AstraZeneca announced an extensive Phase 3 program covering obesity, T2D, and cardiovascular and kidney outcome trials.
Genentech presented Phase 2 CT388-103 data for enicepatide, the once-weekly GLP-1/GIP dual agonist, at the Roche investor event Monday June 8. The 48-week study produced 22.5% placebo-adjusted weight loss in adults with overweight or obesity, with 26% of participants losing more than 30% of body weight and almost 40% reaching at least 25%. Both enicepatide and petrelintide advance into Phase 3, and the planned Phase 2 multi-arm fixed-dose combination of the two starts mid-2026.
Roche presented ZUPREME-1 Phase 2 data for petrelintide, the once-weekly long-acting amylin analog licensed from Zealand Pharma, at the Monday June 8 investor event. The pitch hinges on tolerability: published topline showed up to 10.7% weight loss at 42 weeks versus 1.7% placebo, with discontinuation 4.8% vs 4.9% placebo and no vomiting at the maximally effective dose. Medical Daily framed the readout as a non-incretin option for the estimated 30-40% of patients who quit GLP-1s for GI side effects. Petrelintide advances to Phase 3 alongside enicepatide.
Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.
The ADA closed its 86th Scientific Sessions on June 8 with a formal revision to its Standards of Care that elevates cardiovascular and kidney risk reduction to a co-primary treatment goal alongside glycemic control, ending decades of practice in which HbA1c stood as the dominant benchmark. The shift formalizes a redefinition of diabetes care around the cardio-renal-metabolic axis that GLP-1, SGLT2, and finerenone evidence has driven, and pushes earlier GLP-1 and SGLT2 use from diabetes diagnosis.
A Medscape ADA wrap on June 8 framed the post-GLP-1 era taking shape across the meeting: amylin analogs (petrelintide, cagrilintide, eloralintide) targeting GI-intolerance, triagonists (retatrutide), antibody-peptide conjugates (Amgen's maridebart cafraglutide/MariTide), and preclinical acceleration through AI peptide-design platforms. Each angle aims at the population gap that current GLP-1 monotherapy leaves: the patients who quit for tolerability, the ones who plateau, and the ones who need additional metabolic effects beyond appetite.
The 86th ADA Scientific Sessions wrapped Monday June 8 after presenting Phase 3 retatrutide TRIUMPH-1/TRANSCEND-T2D-1, CagriSema REIMAGINE 1/2/3, Foundayo ACHIEVE 1-5, survodutide SYNCHRONIZE-1, petrelintide ZUPREME-1, enicepatide CT388-103, elecoglipron VISTA/SOLSTICE, mazdutide GLORY-2/DREAMS-3, zenagamtide Phase 2, plus the inaugural ADA Standards of Care in Overweight and Obesity. The next inflection points: the July 23-24 PCAC peptide-compounding meeting, August 28 ITM-11 PDUFA in NETs, and the Foundayo T2D filing in Q2.
Novo Nordisk presented the full REIMAGINE 1/2/3 Phase 3 program in a Sunday symposium at ADA 2026, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). REIMAGINE 2 (n=2,713; 68 weeks) showed CagriSema 2.4/2.4 mg producing 14.2% weight loss and 1.91% HbA1c reduction versus 10.2% and 1.75% for semaglutide 2.4 mg alone. REIMAGINE 1 (n=189; 40 weeks) showed 13.8% weight loss and 1.8% HbA1c drop vs placebo. REIMAGINE 3 (n=274) showed 12.0% weight loss and a 2.33% HbA1c drop when added to basal insulin.